Logo image of SRT3.DE

SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:SRT3 - DE0007165631

245.5 EUR
+1.75 (+0.72%)
Last: 12/23/2025, 5:36:15 PM
Fundamental Rating

3

SRT3 gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 21 industry peers in the Life Sciences Tools & Services industry. SRT3 may be in some trouble as it scores bad on both profitability and health. SRT3 is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

In the past year SRT3 was profitable.
SRT3 had a positive operating cash flow in the past year.
SRT3 had positive earnings in each of the past 5 years.
SRT3 had a positive operating cash flow in each of the past 5 years.
SRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFSRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

With a Return On Assets value of 1.39%, SRT3 is not doing good in the industry: 76.19% of the companies in the same industry are doing better.
SRT3's Return On Equity of 5.01% is on the low side compared to the rest of the industry. SRT3 is outperformed by 66.67% of its industry peers.
The Return On Invested Capital of SRT3 (4.71%) is worse than 71.43% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SRT3 is in line with the industry average of 9.19%.
Industry RankSector Rank
ROA 1.39%
ROE 5.01%
ROIC 4.71%
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
SRT3.DE Yearly ROA, ROE, ROICSRT3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

SRT3's Profit Margin of 3.80% is on the low side compared to the rest of the industry. SRT3 is outperformed by 76.19% of its industry peers.
In the last couple of years the Profit Margin of SRT3 has declined.
With a Operating Margin value of 14.06%, SRT3 is not doing good in the industry: 61.90% of the companies in the same industry are doing better.
In the last couple of years the Operating Margin of SRT3 has declined.
SRT3 has a Gross Margin of 46.48%. This is in the better half of the industry: SRT3 outperforms 66.67% of its industry peers.
SRT3's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 14.06%
PM (TTM) 3.8%
GM 46.48%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
SRT3.DE Yearly Profit, Operating, Gross MarginsSRT3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SRT3 is destroying value.
Compared to 1 year ago, SRT3 has more shares outstanding
SRT3 has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SRT3 has been reduced compared to a year ago.
SRT3.DE Yearly Shares OutstandingSRT3.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SRT3.DE Yearly Total Debt VS Total AssetsSRT3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

SRT3 has an Altman-Z score of 2.44. This is not the best score and indicates that SRT3 is in the grey zone with still only limited risk for bankruptcy at the moment.
SRT3 has a Altman-Z score of 2.44. This is in the lower half of the industry: SRT3 underperforms 61.90% of its industry peers.
SRT3 has a debt to FCF ratio of 8.92. This is a slightly negative value and a sign of low solvency as SRT3 would need 8.92 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 8.92, SRT3 is doing worse than 61.90% of the companies in the same industry.
SRT3 has a Debt/Equity ratio of 1.28. This is a high value indicating a heavy dependency on external financing.
SRT3 has a Debt to Equity ratio of 1.28. This is in the lower half of the industry: SRT3 underperforms 76.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF 8.92
Altman-Z 2.44
ROIC/WACC0.56
WACC8.35%
SRT3.DE Yearly LT Debt VS Equity VS FCFSRT3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.3 Liquidity

A Current Ratio of 0.95 indicates that SRT3 may have some problems paying its short term obligations.
SRT3's Current ratio of 0.95 is on the low side compared to the rest of the industry. SRT3 is outperformed by 85.71% of its industry peers.
SRT3 has a Quick Ratio of 0.95. This is a bad value and indicates that SRT3 is not financially healthy enough and could expect problems in meeting its short term obligations.
SRT3 has a Quick ratio of 0.49. This is amonst the worse of the industry: SRT3 underperforms 90.48% of its industry peers.
Industry RankSector Rank
Current Ratio 0.95
Quick Ratio 0.49
SRT3.DE Yearly Current Assets VS Current LiabilitesSRT3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 59.34% over the past year.
The earnings per share for SRT3 have been decreasing by -11.87% on average. This is quite bad
SRT3 shows a small growth in Revenue. In the last year, the Revenue has grown by 5.82%.
SRT3 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.10% yearly.
EPS 1Y (TTM)59.34%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%24.14%
Revenue 1Y (TTM)5.82%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%6.25%

3.2 Future

SRT3 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.29% yearly.
Based on estimates for the next years, SRT3 will show a quite strong growth in Revenue. The Revenue will grow by 8.99% on average per year.
EPS Next Y22.69%
EPS Next 2Y21.53%
EPS Next 3Y22.9%
EPS Next 5Y19.29%
Revenue Next Year5.43%
Revenue Next 2Y6.87%
Revenue Next 3Y8.82%
Revenue Next 5Y8.99%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SRT3.DE Yearly Revenue VS EstimatesSRT3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B
SRT3.DE Yearly EPS VS EstimatesSRT3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6 8 10

1

4. Valuation

4.1 Price/Earnings Ratio

SRT3 is valuated quite expensively with a Price/Earnings ratio of 53.84.
SRT3's Price/Earnings ratio is rather expensive when compared to the industry. SRT3 is more expensive than 80.95% of the companies in the same industry.
When comparing the Price/Earnings ratio of SRT3 to the average of the S&P500 Index (26.61), we can say SRT3 is valued expensively.
With a Price/Forward Earnings ratio of 40.56, SRT3 can be considered very expensive at the moment.
76.19% of the companies in the same industry are cheaper than SRT3, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of SRT3 to the average of the S&P500 Index (24.01), we can say SRT3 is valued expensively.
Industry RankSector Rank
PE 53.84
Fwd PE 40.56
SRT3.DE Price Earnings VS Forward Price EarningsSRT3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

SRT3's Enterprise Value to EBITDA is on the same level as the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SRT3 is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 38.41
EV/EBITDA 23.89
SRT3.DE Per share dataSRT3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as SRT3's earnings are expected to grow with 22.90% in the coming years.
PEG (NY)2.37
PEG (5Y)N/A
EPS Next 2Y21.53%
EPS Next 3Y22.9%

4

5. Dividend

5.1 Amount

With a yearly dividend of 0.40%, SRT3 is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.54, SRT3 pays a bit more dividend than its industry peers.
With a Dividend Yield of 0.40, SRT3 pays less dividend than the S&P500 average, which is at 1.87.
Industry RankSector Rank
Dividend Yield 0.4%

5.2 History

The dividend of SRT3 has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

37.92% of the earnings are spent on dividend by SRT3. This is a low number and sustainable payout ratio.
The dividend of SRT3 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP37.92%
EPS Next 2Y21.53%
EPS Next 3Y22.9%
SRT3.DE Yearly Income VS Free CF VS DividendSRT3.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
SRT3.DE Dividend Payout.SRT3.DE Dividend Payout, showing the Payout Ratio.SRT3.DE Dividend Payout.PayoutRetained Earnings

SARTORIUS AG-VORZUG

FRA:SRT3 (12/23/2025, 5:36:15 PM)

245.5

+1.75 (+0.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-16 2025-10-16/bmo
Earnings (Next)01-26 2026-01-26/bmo
Inst Owners4.42%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.38B
Revenue(TTM)3.52B
Net Income(TTM)133.70M
Analysts80
Price Target347.12 (41.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.4%
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP37.92%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.85%
Min EPS beat(2)-10.52%
Max EPS beat(2)4.83%
EPS beat(4)1
Avg EPS beat(4)-3.47%
Min EPS beat(4)-10.52%
Max EPS beat(4)4.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.05%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)0.83%
Revenue beat(4)3
Avg Revenue beat(4)1.91%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.38%
PT rev (3m)11.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.45%
EPS NY rev (1m)0%
EPS NY rev (3m)0.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.22%
Valuation
Industry RankSector Rank
PE 53.84
Fwd PE 40.56
P/S 5.23
P/FCF 38.41
P/OCF 21.03
P/B 6.89
P/tB N/A
EV/EBITDA 23.89
EPS(TTM)4.56
EY1.86%
EPS(NY)6.05
Fwd EY2.47%
FCF(TTM)6.39
FCFY2.6%
OCF(TTM)11.68
OCFY4.76%
SpS46.97
BVpS35.63
TBVpS-35.24
PEG (NY)2.37
PEG (5Y)N/A
Graham Number60.46
Profitability
Industry RankSector Rank
ROA 1.39%
ROE 5.01%
ROCE 6.33%
ROIC 4.71%
ROICexc 4.98%
ROICexgc 17.77%
OM 14.06%
PM (TTM) 3.8%
GM 46.48%
FCFM 13.61%
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexgc growth 3Y-35.26%
ROICexgc growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF 8.92
Debt/EBITDA 3.69
Cap/Depr 92.32%
Cap/Sales 11.25%
Interest Coverage 2.65
Cash Conversion 94.72%
Profit Quality 357.97%
Current Ratio 0.95
Quick Ratio 0.49
Altman-Z 2.44
F-Score7
WACC8.35%
ROIC/WACC0.56
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)59.34%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%24.14%
EPS Next Y22.69%
EPS Next 2Y21.53%
EPS Next 3Y22.9%
EPS Next 5Y19.29%
Revenue 1Y (TTM)5.82%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%6.25%
Revenue Next Year5.43%
Revenue Next 2Y6.87%
Revenue Next 3Y8.82%
Revenue Next 5Y8.99%
EBIT growth 1Y18.65%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year101.8%
EBIT Next 3Y38.51%
EBIT Next 5Y26.81%
FCF growth 1Y123.33%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y6.61%
OCF growth 3Y4.07%
OCF growth 5Y20.79%

SARTORIUS AG-VORZUG / SRT3.DE FAQ

What is the ChartMill fundamental rating of SARTORIUS AG-VORZUG (SRT3.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRT3.DE.


What is the valuation status for SRT3 stock?

ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS AG-VORZUG (SRT3.DE). This can be considered as Overvalued.


Can you provide the profitability details for SARTORIUS AG-VORZUG?

SARTORIUS AG-VORZUG (SRT3.DE) has a profitability rating of 3 / 10.


Can you provide the PE and PB ratios for SRT3 stock?

The Price/Earnings (PE) ratio for SARTORIUS AG-VORZUG (SRT3.DE) is 53.84 and the Price/Book (PB) ratio is 6.89.


What is the expected EPS growth for SARTORIUS AG-VORZUG (SRT3.DE) stock?

The Earnings per Share (EPS) of SARTORIUS AG-VORZUG (SRT3.DE) is expected to grow by 22.69% in the next year.